

5 September 2022

Incidence and treatment of Haemophilia A

Enquiry:

I am analysing the incidence and treatment of Haemophilia A. Could you kindly provide answers to the following questions.

Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

Q2. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

Response:

The information requested is exempt under Section 21: Information already reasonably accessible. The information requested is readily available from the National Haemophilia Database (NHD). We attach information on how to make a request to the NHD.